Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole plus neoadjuvant chemotherapy and PD-1 inhibitor for early or locally advanced triple-negative breast cancer
ChiCTR2500098742Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of posaconazole in breast cancer and triple-negative breast cancer (TNBC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: Total pathological complete response and Objective response rate. Started Mar 2025; status: recruiting.
02
Drugs
posaconazole
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500098742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098742.